<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114162">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707667</url>
  </required_header>
  <id_info>
    <org_study_id>SPD555-403</org_study_id>
    <nct_id>NCT01707667</nct_id>
  </id_info>
  <brief_title>Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity</brief_title>
  <official_title>An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the different effects of prucalopride and PEG 3350 + electrolytes on colon motor
      activity in subjects that are chronically constipated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Number of High-Amplitude Propagating Contractions (HAPC)</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve (AUC) for Prucalopride</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Amplitude of HAPC</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and consistency of bowel movements as assessed by the Bristol Stool Scale</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Between Occurrence of Bowel Movement and Last HAPC Preceding that Bowel Movement</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first HAPC</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Propagation Velocity of HAPC</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of HAPC</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motility Index</measure>
    <time_frame>over 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 3350</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prucalopride</intervention_name>
    <description>One 2 mg tablet orally administered on Day 1</description>
    <arm_group_label>Prucalopride</arm_group_label>
    <other_name>Resolor (Marketed name in Europe)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG 3350</intervention_name>
    <description>13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water.  Administered twice orally on Day 1(once in the morning and once prior to lunch).</description>
    <arm_group_label>PEG 3350</arm_group_label>
    <other_name>Movicol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic constipation

          -  Male or female ages 18-75 years

          -  Non-pregnant, non-lactating female

        Exclusion Criteria:

          -  Drug-induced constipation

          -  Subjects suffering from secondary causes of chronic constipation, such as:

               -  Endocrine disorders, e.g. hypopituitarism, hypothyroidism, hypercalcemia,
                  pseudohypoparathyroidism, pheochromocytoma or glucagon-producing tumors, unless
                  these are controlled by appropriate medical therapy.

               -  Metabolic disorders, e.g. porphyria, uremia, hypokalemia or amyloid neuropathy,
                  unless these are controlled by appropriate medical therapy

               -  Neurological disorders, e.g. Parkinson's disease, cerebral tumors,
                  cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis,
                  hypoganglionosis, hyperganglionosis, autonomic neuropathy or neuropathy due to
                  chemotherapy, spinal cord injury, Chaga's disease, or major depression

               -  Surgery.

          -  Subjects with insulin-dependent diabetes mellitus

          -  Rectal evacuation disorder/outlet obstruction

          -  Subjects with intestinal perforation or obstruction

          -  Severe renal impairment

          -  Subjects with a history of alcohol or drug abuse

          -  Subjects with lactose intolerance

          -  Subjects with clinically significant cardiac, vascular, liver, pulmonary, endocrine,
             neurological or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leuven, University Hospital, Department of Gastroenterology, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma Foundation for Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITY OF LEUVEN, UNVERSITY HOSPITAL, Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>Whitechapel, London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>October 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
